Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 274 publications

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).

Journal: Molecular pharmaceutics
Published: September 07, 2025

Parkinson Disease.

Parkinson Disease.

Journal: Continuum (Minneapolis, Minn.)
Published: August 01, 2025

Adenosine A2A receptor activation in the nucleus accumbens decreases motivation for wheel running in male mice.

Adenosine A2A receptor activation in the nucleus accumbens decreases motivation for wheel running in male mice.

Journal: Psychopharmacology
Published: July 11, 2025

Camptocormia in Parkinson's disease: state of the art and future directions.

Camptocormia in Parkinson's disease: state of the art and future directions.

Journal: Journal of neurology
Published: July 03, 2025

Safety Profile of Istradefylline in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS.

Safety Profile of Istradefylline in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials and Disproportionality Analysis Using FAERS.

Journal: Journal of geriatric psychiatry and neurology
Published: May 21, 2025

The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson's Disease.

The Anti-Parkinsonian A2A Receptor Antagonist Istradefylline (KW-6002) Attenuates Behavioral Abnormalities, Neuroinflammation, and Neurodegeneration in Cerebral Ischemia: An Adenosinergic Signaling Link Between Stroke and Parkinson's Disease.

Journal: International journal of molecular sciences
Published: May 02, 2025

Treatment of Motor Symptoms of Parkinson's Disease.

Treatment of Motor Symptoms of Parkinson's Disease.

Journal: Neurologic clinics
Published: April 04, 2025

Adenosine A2A receptor and glial glutamate transporter GLT-1 are synergistic targets to reduce brain hyperexcitability after traumatic brain injury in mice.

Adenosine A2A receptor and glial glutamate transporter GLT-1 are synergistic targets to reduce brain hyperexcitability after traumatic brain injury in mice.

Journal: Neuropharmacology
Published: March 25, 2025

Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1δ blockers.

Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1δ blockers.

Journal: European journal of pharmacology
Published: March 17, 2025

Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2.

Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2.

Journal: The Journal of pharmacology and experimental therapeutics
Published: March 13, 2025

Impact of Adjunctive Istradefylline on Dyskinesia Onset in Patients with Parkinson's Disease Exhibiting Wearing-Off: An Open-Label Randomized Controlled Trial.

Impact of Adjunctive Istradefylline on Dyskinesia Onset in Patients with Parkinson's Disease Exhibiting Wearing-Off: An Open-Label Randomized Controlled Trial.

Journal: Neurology and therapy
Published: March 03, 2025

Safety and Efficacy of Istradefylline in Parkinson's Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials.

Safety and Efficacy of Istradefylline in Parkinson's Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials.

Journal: Journal of movement disorders
Published: February 27, 2025
Showing 1-12 of 274

Last Updated: 10/31/2025